Literature DB >> 20044784

Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene.

Luca Cantarini1, Orso Maria Lucherini, Gabriele Simonini, Mauro Galeazzi, Cosima Tatiana Baldari, Rolando Cimaz.   

Abstract

Systemic juvenile idiopathic arthritis (SJIA) is a disorder characterized by arthritis in children starting before 16 years of age associated with daily high fever, persisting for more than 2 weeks, and at least one of the following clinical features: evanescent cutaneous rash, lymphadenopathy, serositis or hepatosplenomegaly. SJIA patients carry a significantly higher frequency of MEFV mutations, the gene responsible for familial Mediterranean fever, and may be characterized by a more aggressive disease. In this line, we describe a 9-year-old girl affected with SJIA who carried a heterozygous G196W mutation in MEFV. Our patient was characterized by an aggressive disease course, resistance to conventional immunosuppressive agents and developed renal amyloidosis just 2 years after the disease onset.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20044784     DOI: 10.1007/s00296-009-1331-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

Review 2.  Amyloidosis in juvenile chronic arthritis.

Authors:  J David
Journal:  Clin Exp Rheumatol       Date:  1991 Jan-Feb       Impact factor: 4.473

3.  Why can we no longer find juvenile idiopathic arthritis-associated amyloidosis in childhood or in adolescence in Finland?

Authors:  K Immonen; H A Savolainen; M Hakala
Journal:  Scand J Rheumatol       Date:  2007 Sep-Oct       Impact factor: 3.641

4.  Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.

Authors:  R E Petty; T R Southwood; J Baum; E Bhettay; D N Glass; P Manners; J Maldonado-Cocco; M Suarez-Almazor; J Orozco-Alcala; A M Prieur
Journal:  J Rheumatol       Date:  1998-10       Impact factor: 4.666

5.  Juvenile psoriatic arthritis carrying familial Mediterranean fever gene mutations in a 14-year-old Turkish girl.

Authors:  Betul Sozeri Yeniay; Neslihan Edeer Karaca; Seciye Eda Yuksel; Levent Midyat; Necil Kutukculer
Journal:  J Dermatol       Date:  2007-05       Impact factor: 4.005

Review 6.  Update on treatment of arthritis in children: new treatments, new goals.

Authors:  Daniel J Lovell
Journal:  Bull NYU Hosp Jt Dis       Date:  2006

7.  Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis.

Authors:  E Aganna; P N Hawkins; S Ozen; T Pettersson; A Bybee; S A McKee; H J Lachmann; L Karenko; A Ranki; A Bakkaloglu; N Besbas; R Topaloglu; H M Hoffman; G A Hitman; P Woo; M F McDermott
Journal:  Genes Immun       Date:  2004-06       Impact factor: 2.676

8.  MEFV mutations in systemic onset juvenile idiopathic arthritis.

Authors:  N A Ayaz; S Ozen; Y Bilginer; M Ergüven; E Taşkiran; E Yilmaz; N Beşbaş; R Topaloğlu; A Bakkaloğlu
Journal:  Rheumatology (Oxford)       Date:  2008-11-04       Impact factor: 7.580

9.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Authors:  Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Shuji Takei; Naomi Iwata; Hiroaki Umebayashi; Takuji Murata; Mari Miyoshi; Minako Tomiita; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

10.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.

Authors:  Virginia Pascual; Florence Allantaz; Edsel Arce; Marilynn Punaro; Jacques Banchereau
Journal:  J Exp Med       Date:  2005-04-25       Impact factor: 14.307

  10 in total
  6 in total

1.  MEFV mutations in Egyptian children with systemic-onset juvenile idiopathic arthritis.

Authors:  Hala M Lotfy; Manal E Kandil; Marianne Samir Makboul Issac; Samia Salah; Nagwa Abdallah Ismail; Mohamed A Abdel Mawla
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

Review 2.  Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.

Authors:  Ayush Gupta; Narendra Kumar Bagri; Saroj Kumar Tripathy; Adarsh Barwad; Ravi Hari Phulware; Pankaj Hari
Journal:  Rheumatol Int       Date:  2019-07-04       Impact factor: 2.631

Review 3.  Molecular genetic analysis for periodic fever syndromes: a supplemental role for the diagnosis of adult-onset Still's disease.

Authors:  Hongbin Li; Irina Abramova; Sandra Chesoni; Qingping Yao
Journal:  Clin Rheumatol       Date:  2018-06-17       Impact factor: 2.980

4.  Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.

Authors:  Xuefeng B Ling; Kenneth Lau; Chetan Deshpande; Jane L Park; Diana Milojevic; Claudia Macaubas; Chris Xiao; Viorica Lopez-Avila; John Kanegaye; Jane C Burns; Harvey Cohen; James Schilling; Elizabeth D Mellins
Journal:  Clin Proteomics       Date:  2010-09-30       Impact factor: 3.988

5.  Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases.

Authors:  Rezan Topaloglu; Ezgi Deniz Batu; Diclehan Orhan; Seza Ozen; Nesrin Besbas
Journal:  Pediatr Nephrol       Date:  2015-11-12       Impact factor: 3.714

Review 6.  Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review.

Authors:  Songkiat Chantarogh; Soamarat Vilaiyuk; Thipwimol Tim-Aroon; Suchin Worawichawong
Journal:  BMC Nephrol       Date:  2017-05-12       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.